ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2771

PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica

Niklas Thomas Baerlecken1, Torsten Witte2, Marco Amedeo Cimmino3 and Dario Camellino4, 1Clinical Immunology and Rheumatology, MD, Hannover, Germany, 2Medical School Hannover, MD, Hanover, Germany, 3Clinica Reumatologica, Università di Genova, Genova, Italy, 4Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: Antibodies, polymyalgia rheumatica and positron emission tomography (PET)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before glucocorticoid treatment was initiated. In that study, it remained unclear however, whether the PMR patients may have suffered from additional undiagnosed GCA. Therefore, we now measured antibodies against FHCP in PMR patients in whom GCA had been excluded by FDG-PET scan.

Methods

Sera of 63 patients were studied that presented initially with symptoms of PMR. A PET-CT had been performed in all patients and revealed large vessel vasculitis in 27 of these patients (GCA/PMR), whereas 36 had no signs of vasculitis (PMR). In a single-blinded study, we measured anti-FHCP in these patients and in a control group of patients with rheumatic diseases (RD, n=26), malignant diseases (MD, n=15) and infectious febrile diseases (IFD, n=22).

In the ELISA 3 peptides of the ferritin heavy chain were used as antigens: A19-45 (AAINRQINLELYASYVYLSMSYYFDRF), A79-104 (GRIFQDIKKPCDDWESGLNAMECA) and A105-143 (LHEKNVNQSLELHKLATDKNDPHLCFIETHYLNEQVK). 

Results

The frequency of antibodies against A19-45 were 38/63 (60%) in all PMR patients and 14/63 (22%) in controls (p<0.0001), of antibodies against A79-104 30/63 (48%) in all PMR patients and 9/63 (14%) in controls (p=0.0001) and of antibodies against A105-143 38/63 (60%) in PMR and 12/63 (19%) in controls (p<0.0001). There were no differences within the controls considering all antigens.

Comparing the patients with and without vascular involvement in PET-CT, the frequencies of antibodies against A19-45 (18/27 (67%) and 20/36 (56%), (p=0.53)), against A79-104 (14/27 (52%) and 16/36 (44%) (p=0.74)) and against A105-143 (19/27 (70%) and 19/36 (53%) (p=0.25)) were not different. 

Conclusion

This single-blinded study confirms the frequency of anti-FHCP in a different cohort. Anti-FHCP are associated with both GCA/PMR and PMR only.


Disclosure:

N. T. Baerlecken,
None;

T. Witte,
None;

M. A. Cimmino,
None;

D. Camellino,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2014

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pet-ct-imaging-and-association-of-ferritin-autoantibodies-in-polymyalgia-rheumatica/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology